Extended follow-up of children in a phase2b trial of the GMZ2 malaria vaccine

Abstract

The GMZ2/alum candidate malaria vaccine had an efficacy of 14% (95% confidence interval [CI]: 3.6%, 23%) against clinical malaria over 6 months of follow-up in a phase2b multicentre trial in chil dren 1–5 years of age. Here we report the extended follow up of safety and efficacy over 2 years. Methods: A total of 1849 (GMZ2 = 926, rabies = 923) children aged 12–60 months were randomized to receive intramuscularly, either 3 doses of 100 lg GMZ2/alum or 3 doses of rabies vaccine as control 28 days apart. The children were followed-up for 24 months for clinical malaria episodes and adverse events. The primary endpoint was documented fever with parasitaemia of at least 5000/lL. Results: There were 2,062 malaria episodes in the GMZ2/alum group and 2,115 in the rabies vaccine group in the intention-to-treat analysis, vaccine efficacy (VE) of 6.5% (95%: CI 1.6%, 14.0%). In children aged 1–2 years at enrolment, VE was 3.6% (95 %CI: 9.1%, 14.8%) in the first year and 4.1% (95 %CI: 18.7%, 87%) in the second year. In children aged 3–5 years at enrolment VE was 19.9% (95 %CI: 7.7%, 30.4%) in the first year and 6.3% (95 %CI: 10.2%, 20.3%) in the second year (interaction by year, P = 0.025, and by age group, P = 0.085). A total of 187 (GMZ2 = 91, rabies = 96) serious adverse events were recorded in 167 individuals over the entire period of the study. There were no GMZ2 vaccine related serious adverse events. Conclusions: GMZ2/alum was well tolerated. Follow-up over 2 years confirmed a low level of vaccine efficacy with slightly higher efficacy in older children, which suggests GMZ2 may act in concert with naturally acquired immunity.